TARPEYO WAS SPECIFICALLY
DESIGNED TO TREAT IgA NEPHROPATHY
TARPEYO is the first FDA-approved medicine to reduce proteinuria in adults with IgA Nephropathy who are at high risk of disease progression.

Specifically designed for and studied in IgA Nephropathy
TARPEYO is the first approved therapy that was specifically designed for IgAN

Targets a source of IgA Nephropathy in the gut
TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgAN. TARPEYO can reduce the amount of IgA1 antibody.* IgA1 can build up in the kidneys, which can cause IgAN

Significantly reduced protein in urine
TARPEYO reduced protein by 34% versus 5% in patients who received placebo with blood pressure medication†

Once-daily oral medicine
4 capsules of TARPEYO should be taken once a day and swallowed whole Please see information for how to take TARPEYO and what to avoid while taking TARPEYO here.
*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
†In Part A of the TARPEYO clinical study, 97 patients received TARPEYO plus blood pressure medication, and 102 patients received placebo plus blood pressure medication.
WHAT IS UNIQUE ABOUT TARPEYO?
TARPEYO is made up of the active ingredient budesonide. The TARPEYO capsule was specifically designed with targeted-release technology to deliver treatment to an area of the gut thought to play a role in IgA Nephropathy.‡

‡It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
HOW WAS TARPEYO STUDIED?
TARPEYO was specifically studied in a large trial of patients with IgA Nephropathy
Part A of the clinical study of TARPEYO was the pivotal placebo-controlled efficacy and safety trial that served as the basis for the FDA accelerated approval
97
patients received TARPEYO plus blood pressure medication
102
patients received placebo plus blood pressure medication
- Primary objective: See how TARPEYO reduced high levels of protein in the urine (proteinuria) after 9 months of treatment, as measured by urine protein-to-creatinine ratio (UPCR)
- eGFR was a selected secondary objective in this part of the study
- Part B of the clinical study is a follow-up study for full approval that will assess eGFR over 2 years for patients who were treated with TARPEYO or placebo in Part A
TARPEYO STUDY RESULTS
TARPEYO significantly lowered levels of protein in urine at 9 months§


§In Part A of the TARPEYO clinical study, 97 patients received TARPEYO plus blood pressure medication, and 102 patients received placebo plus blood pressure medication.
eGFR data at 9 months


The impact of TARPEYO on eGFR is being followed in Part B of the study. It has not been established whether TARPEYO has demonstrated a benefit in slowing kidney function decline in patients with IgA Nephropathy.
TARPEYO SAFETY PROFILE
TARPEYO may cause serious side effects, including:
TARPEYO may cause serious side effects, including:
- Effects of having too much corticosteroid medicine in your blood (hypercorticism), adrenal suppression, and risk of immunosuppression
- Please see detailed Important Safety Information
THE MOST COMMON SIDE EFFECTS REPORTED BY PATIENTS IN THE CLINICAL STUDY OF TARPEYO


APPROXIMATELY 90% OF PATIENTS IN THE CLINICAL STUDY STAYED ON TARPEYO TREATMENT